Literature DB >> 35869255

A blockchain-based framework to support pharmacogenetic data sharing.

F Albalwy1,2,3, J H McDermott4,5, W G Newman4,5, A Brass6,7, A Davies7.   

Abstract

The successful implementation of pharmacogenetics (PGx) into clinical practice requires patient genomic data to be shared between stakeholders in multiple settings. This creates a number of barriers to widespread adoption of PGx, including privacy concerns related to the storage and movement of identifiable genomic data. Informatic solutions that support secure and equitable data access for genomic data are therefore important to PGx. Here we propose a methodology that uses smart contracts implemented on a blockchain-based framework, PGxChain, to address this issue. The design requirements for PGxChain were identified through a systematic literature review, identifying technical challenges and barriers impeding the clinical implementation of pharmacogenomics. These requirements included security and privacy, accessibility, interoperability, traceability and legal compliance. A proof-of-concept implementation based on Ethereum was then developed that met the design requirements. PGxChain's performance was examined using Hyperledger Caliper for latency, throughput, and transaction success rate. The findings clearly indicate that blockchain technology offers considerable potential to advance pharmacogenetic data sharing, particularly with regard to PGx data security and privacy, large-scale accessibility of PGx data, PGx data interoperability between multiple health care providers and compliance with data-sharing laws and regulations.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35869255     DOI: 10.1038/s41397-022-00285-5

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.245


  32 in total

Review 1.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

2.  The NHS's care.data scheme: what are the risks to privacy?

Authors:  Jon Hoeksma
Journal:  BMJ       Date:  2014-02-17

3.  The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Authors:  R A Wilke; L B Ramsey; S G Johnson; W D Maxwell; H L McLeod; D Voora; R M Krauss; D M Roden; Q Feng; R M Cooper-Dehoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2012-05-23       Impact factor: 6.875

Review 4.  Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now.

Authors:  Kristin W Weitzel; Larisa H Cavallari; Lawrence J Lesko
Journal:  Pharm Res       Date:  2017-05-02       Impact factor: 4.200

5.  Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences.

Authors:  Katherine Payne; Emily A Fargher; Stephen A Roberts; Karen Tricker; Rachel A Elliott; Julie Ratcliffe; William G Newman
Journal:  Value Health       Date:  2011-01       Impact factor: 5.725

Review 6.  Pharmacogenomics: the genetics of variable drug responses.

Authors:  Dan M Roden; Russell A Wilke; Heyo K Kroemer; C Michael Stein
Journal:  Circulation       Date:  2011-04-19       Impact factor: 29.690

7.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

Review 8.  Pharmacogenomics.

Authors:  Dan M Roden; Howard L McLeod; Mary V Relling; Marc S Williams; George A Mensah; Josh F Peterson; Sara L Van Driest
Journal:  Lancet       Date:  2019-08-05       Impact factor: 79.321

9.  Pharmacogenomics in the UK National Health Service: opportunities and challenges.

Authors:  Richard M Turner; William G Newman; Elvira Bramon; Christine J McNamee; Wai Lup Wong; Siraj Misbah; Sue Hill; Mark Caulfield; Munir Pirmohamed
Journal:  Pharmacogenomics       Date:  2020-10-29       Impact factor: 2.533

10.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.

Authors:  John J Lima; Cameron D Thomas; Julia Barbarino; Zeruesenay Desta; Sara L Van Driest; Nihal El Rouby; Julie A Johnson; Larisa H Cavallari; Valentina Shakhnovich; David L Thacker; Stuart A Scott; Matthias Schwab; Chakradhara Rao S Uppugunduri; Christine M Formea; James P Franciosi; Katrin Sangkuhl; Andrea Gaedigk; Teri E Klein; Roseann S Gammal; Takahisa Furuta
Journal:  Clin Pharmacol Ther       Date:  2020-09-20       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.